Stock Analysis
Zimmer Biomet Holdings, Inc. (ZBH) Stock Analysis
Zimmer Biomet Holdings, Inc. (ZBH) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Zimmer Biomet Holdings, Inc. (ZBH) currently has an AIQ Score of 52/100, indicating a neutral setup. Value is the strongest factor at 67/100. Momentum is the weakest current factor at 28/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
ZBH at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $93.49 |
| AIQ Score | 52/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Sell |
| Market Cap | $19.23B |
| P/E Ratio | 11.72 |
| Forward P/E | — |
| EPS | $1.03 |
| Revenue TTM | $2.18B |
| Dividend Yield | 0.00% |
| Beta | 0.46 |
| Volume | 1.88M |
| 52-week range | $79.12-$106.88 |
| RSI 14 | 26.16 |
| 50-Day SMA | $95.33 |
| 200-Day SMA | $91.44 |
| Analyst Price Target | $100.36 |
| Next Earnings | Nov 4, 2026 |
ZBH
OverviewZBH Stock Analysis Summary
Zimmer Biomet Holdings, Inc. (ZBH) currently has an AIQ Score of 52/100, indicating a neutral setup. Value is the strongest factor at 67/100. Momentum is the weakest current factor at 28/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, ZBH has AIQ Score of 52/100 with Value base of 67/100 and fading Momentum at 28/100. Wait for component alignment before adding exposure.
Value (67/100) leads while Momentum (28/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 1.14% stock move · ZBH classified in Medical - Devices.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is ZBH Bullish or Bearish Right Now?
ZBH currently has a neutral overall setup. Value is the strongest factor at 67/100, while Momentum is weakest at 28/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Analyst target implies +7.35% upside from the latest quote.
- - Momentum is weak at 28/100.
- - Technical consensus has more sell votes than buy votes (32 vs 11).
Current Consensus
ZBH's Technical Analysis Consensus is currently Sell, with 11 buy, 2 neutral, and 32 sell votes. ZBH's 14-day RSI is 26.16, which places the stock in an oversold momentum range. ZBH's beta is 0.46, indicating lower market sensitivity than the broad market.
What Changed in ZBH?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the ZBH Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
ZBH Decision Framework
Public evidence layers, setup checks, and risk context for Zimmer Biomet Holdings, Inc..
Zimmer Biomet Holdings, Inc. (ZBH) Stock Analysis
Zimmer Biomet Holdings, Inc. has an AIQ Score of 52/100 in a Neutral regime. Value is strongest at 67/100. Beta is 0.46, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | ZBH is in a Neutral AIQ regime with score 52/100. |
| Signal Conflict | The primary conflict is that value leads at 67/100 while momentum lags at 28/100. |
| Factor Evidence | Momentum 28/100 · Value 67/100 · Quality 57/100 · Risk 54/100 · Sentiment 64/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Value is the strongest factor at 67/100.
Momentum is 28/100 and RSI (14) is 26.2.
ZBH is in a Neutral regime at 52/100.
Risk factor is 54/100 with beta 0.46 and annual volatility 31.98%.
Current conflict: value leads at 67/100 while momentum lags at 28/100.
ZBH Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
ZBH Fundamentals
ZBH valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
ZBH Technical Analysis
ZBH technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
ZBH Stock Catalysts
Track ZBH earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
ZBH Dividend Analysis
ZBH dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
ZBH Financial Data
ZBH revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
ZBH Risk Analysis
ZBH volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
ZBH Stock News
ZBH stock news, market tone, recent headlines, and catalyst context.
ZBH vs Medical Devices Peers
Current peer cohort: ZBH · ABT · ALGN · AVTR · BAX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| ZBH Current stock | 52/100 | 67/100 | 28/100 | 54/100 | -0.24 | 31.98% | Current |
| ABT Abbott Laboratories | 45/100 | 48/100 | 20/100 | 57/100 | -0.9 | 27.02% | ZBH vs ABT |
| ALGN Align Technology | 53/100 | 63/100 | 23/100 | 50/100 | 0.42 | 39.24% | ZBH vs ALGN |
| AVTR Avantor | 55/100 | 64/100 | 66/100 | 60/100 | 0.5 | 51.65% | ZBH vs AVTR |
| BAX Baxter International | 42/100 | 69/100 | 30/100 | 54/100 | 0.11 | 43.45% | ZBH vs BAX |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 11, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts6 recent quarterly periods are available for review.
Checked Sep 12, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching ZBH
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for ZBH
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
ZBH Stock FAQ
What is ZBH stock price today?
Zimmer Biomet Holdings, Inc.'s current stock price is $93.49. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is ZBH bullish or bearish right now?
ZBH's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is ZBH's market cap?
ZBH's market cap is $19.23B based on the latest completed market-close snapshot from Sep 11, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is ZBH's current P/E ratio?
ZBH's current P/E ratio is 11.72 based on the latest completed market-close snapshot from Sep 11, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is ZBH's RSI?
ZBH's 14-day RSI is 26.16 based on the latest completed market-close snapshot from Sep 11, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is ZBH above its 50-day and 200-day moving averages?
ZBH is -1.93% from its 50-day SMA and 2.24% from its 200-day SMA based on the latest completed market-close snapshot from Sep 11, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is ZBH's next earnings date?
ZBH's next earnings date is currently listed as Nov 4, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does ZBH pay a dividend?
ZBH's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 11, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.